Accelerated Bookbuild Offering
Transgene
Joint Global CoordinatorKempen & Co acted as Joint Global Coordinator in Transgene’s €34.1m capital increase
Transaction highlights
- Placement of 13.9m new shares at a subscription price of €2.45 per share, generating gross proceeds of approximately €34.1m
- Transgene intents to use circa €25m of the net proceeds to finalise clinical studies, circa €4m to launch the clinical development of new oncolytic viruses based on the Invir.IOTM platform, and the remainder of the proceeds to finance R&D and operational costs
- Existing shareholders Institut Mérieux and SITAM Belgium participated in the capital increase for a total amount of €25m and €1.67m , respectively. Several specialised healthcare investors, including Invus, also participated in the transaction
- This transaction marks the third transaction in which Kempen & Co assisted the Company following a capital increase in 2016 and 2019, underpinning our ambition to be a long-term partner for our clients
- In 2021, year to date, Kempen & Co has already executed 17 transactions for European life sciences companies
Company description
Transgene is a French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilise viral vector technology with the goal of indirectly or directly killing cancerous cells. The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualised therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
Background Kempen & Co life sciences & healthcare
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator & Joint Bookrunner in the SEK 141m Capital Increase by Immunicum
- Lead Manager in Molecular Partners’ USD 63.8m Initial Public Offering on Nasdaq
- Joint Bookrunner in the SEK 301m Capital Increase by Q-linea
- Co-Manager in the USD 176m Nasdaq Initial Public Offering by Achilles Therapeutics
- Joint Bookrunner in the €30m Capital Increase by GenSight Biologics
- Lead Manager in the USD 101m Nasdaq Initial Public Offering by LAVA Therapeutics
- Joint Bookrunner in the USD 120m Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
- Joint Bookrunner in the SEK 1.1 billion Capital Increase by Oncopeptides
- Joint Global Coordinator and Joint Bookrunner in the SEK 962m Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the €22.5m Capital Increase by Sequana Medical
- Co-Manager in the USD 115m US Public Offering by Y-mAbs Therapeutics
- Co-Manager in the USD 115m US Public Offering by Autolus Therapeutics
- Co-Manager in the USD 190m Nasdaq Initial Public Offering by Pharvaris
- Bookrunner in the USD 518m US Public Offering by CureVac
- Lead Manager in the USD 120m US Public Offering by Merus
- Financial Adviser to DCprime in its merger with Immunicum
- Joint Bookrunner in the SEK 564m Capital Increase by Cantargia
- Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2m
- Placement Agent in Investinor’s Secondary Sell-Down of c. 4m shares in Calliditas Therapeutics
- Lead Manager in the USD 95.1m Nasdaq Initial Public Offering by Galecto
- Joint Bookrunner in the €31m Capital Increase by Sensorion
- Bookrunner in the USD 245m Nasdaq Initial Public Offering by CureVac
- Co-Manager in the USD 49m US Public Offering by Centogene
- Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
- Joint Bookrunner in the CHF 80.2m Capital Increase by Molecular Partners
- Co-Manager in the USD 690m US Public Offering by Ascendis Pharma
- Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253m
- Joint Global Coordinator and Joint Bookrunner in the €61.8m Initial Public Offering by Hyloris Pharmaceuticals
Contact
Lees meer over:
Transactions
No transactions found
Placing
Capital Increase
US Public Offering
Sale to
Portfolio company of
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Mandatory Convertible Bond Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Capital increase
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
on Nasdaq
Initial Public Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Capital increase
Private Placement
US Public Offering
Initial Public Offering
US Public Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
Debt financing
US Public Offering
US Public Offering
Green Revolving Credit Facility
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
US public offering
Rights issue
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Fundraise
Accelerated bookbuild offering
Rights issue Public offer by German listed ADLER Real Estate
for Israeli listed
Public offer by German Vonovia
Accelerated bookbuild offering
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
US public offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Public offer by
for
Public takeover by German Vonovia
For Austrian Conwert
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Management participation advisory in dual-track sale process
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Accelerated bookbuild and private placement
Rights issue